Abstract 1559P
Background
Advancement of comprehensive genomic profiling (CGP) technology enables genomic medicine to emerge as a promising cancer treatment selection approach. As clinical implementation expands, concerns arise regarding equity of access and clinical utility. This study investigated the influence of ethnicity, socioeconomic status, and other factors on access to genomic testing at a trials unit in the UK. The clinical impact was also studied.
Methods
A retrospective review of patients referred for CGP between 2015 to 2024 was conducted. The impact of access by age, cancer types, ethnicity, and socioeconomic status defined by Index of Multiple Deprivation (IMD,1 - most deprived; 10 - least deprived) was assessed by comparing against population data from the UK Office for National Statistics. Clinical utility metrics including matching rates to targeted therapies, frequency of genomic aberrations, sequencing success rate, turnaround time were assessed based on medical records.
Results
Data from 406 patients was compared against the catchment area population. Patients from more deprived socioeconomic backgrounds were less likely to partake in CGP (p < 0.001). Black and mixed ethnic background were under-represented in the analysis population (p < 0.001). Clinical utility aligned with larger studies but only 31 (8.2%) patients were started on a matched targeted therapy. Table: 1559P
Summary of demographic characteristics
Age [years, median (range)] | 59 (24-85) |
External referral, n (%) | 120 (29.6%) |
Female, n (%) | 219 (53.9%) |
Ethnicity, n (%) | |
White | 236 (58.1%) |
Non-white | 73 (18.0%) |
Not recorded | 97 (23.9%) |
Socioeconomic status (IMD), n (%) | |
1-2 | 51 (12.7%) |
3-4 | 98 (24.4%) |
5-6 | 98 (24.4%) |
7-8 | 82 (20.4%) |
9-10 | 72 (18.0%) |
No results | 5 |
Cancer types, n (%) | |
Breast | 37 (9.1%) |
Endocrine | 9 (2.2%) |
Gynaecological | 66 (16.3%) |
Head and Neck | 7 (1.7%) |
Hepatobiliary and Pancreatic | 58 (14.3%) |
Upper GI | 21 (5.2%) |
Lower GI | 132 (32.5%) |
Skin | 4 (1.0%) |
Thoracic | 34 (8.4%) |
Urological | 33 (8.1%) |
Unknown Primary | 5 (1.2%) |
Median prior therapy lines, n | 3 |
Conclusions
Matching rate to targeted therapy or clinical trials remained low. The most common barriers were the lack of actionable mutation, unavailability of trials, and poor performance status. We also identified disparities of access to molecular testing associated with socioeconomic status and ethnicity. Current patient recruitment primarily relies on elective referrals from treating clinicians which could be a factor contributing to the observed disparity. Future efforts should focus on establishing a centralised, automated referral pathway.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Guy's and St Thomas' NHS Foundation Trust.
Funding
Has not received any funding.
Disclosure
J. Spicer: Financial Interests, Institutional, Advisory Board, Compensation to my employer for time providing advice: AstraZeneca, BMS, GSK, RS Oncology; Financial Interests, Personal, Stocks/Shares, Co-founder: Epsilogen; Financial Interests, Personal, Stocks/Shares: Avacta; Financial Interests, Institutional, Local PI, Reimbursement for treatment of patients in trial: Achilles, Roche, Trizell, BergenBio, MSD, Gilead, Iovance; Financial Interests, Institutional, Coordinating PI, Reimbursement for treatment of patients in trial: Starpharma, BMS, IO Biotech, RS Oncology; Non-Financial Interests, Leadership Role, National strategy board: Experimental Cancer Medicine Centres; Non-Financial Interests, Member of Board of Directors, Steering Committee: British Thoracic Oncology Group; Non-Financial Interests, Advisory Role, Advice on licensing decisions for MHRA: CHM Expert Advisory Group on Oncology & Haematology; Non-Financial Interests, Advisory Role, Advice on regulatory approvals: CHM Cancer Vaccines Expert Working Group. D. Sarker: Financial Interests, Personal, Advisory Board: Eisai, Ipsen, Bayer, Surface Oncology, AAA, AbbVie, Boehringer Ingelheim, AstraZeneca, Incyte; Financial Interests, Personal, Invited Speaker: MSD, Bayer, AstraZeneca, Eisai, Servier, Incyte; Financial Interests, Personal, Other, Travel and conference fees: Ipsen; Financial Interests, Personal, Other, Travel and Conference Fees: MiNA Therapeutics; Financial Interests, Institutional, Coordinating PI: UCB, MiNA Therapeutics; Financial Interests, Institutional, Local PI: Eisai, Medivir AB, MSD, Bayer, RedX, GSK, Starpharma, Adaptimmune, Blueprint, H3, Regeneron, Taiho, AstraZeneca, Ipsen; Financial Interests, Institutional, Funding: Roche, Inspirata; Non-Financial Interests, Advisory Role: Medivir, UCB, MiNA Therapeutics. All other authors have declared no conflicts of interest.
Resources from the same session
1564P - Limited participation in breast cancer screening among low-SES women: A matter of engagement or of health literacy?
Presenter: Allegra Ferrari
Session: Poster session 10
1566P - Optimizing participation in lung cancer screening program: Results from the first round in ILYAD study in Lyon University Hospital
Presenter: Emmanuel Grolleau
Session: Poster session 10
1567P - Physicians' adenoma detection rate and the risk of colorectal cancer in sequential screening programs: An observational cohort study
Presenter: Li Xie
Session: Poster session 10
1568P - Challenges in pilot lung cancer screening in Vojvodina, Serbia
Presenter: Jelena Djekic Malbasa
Session: Poster session 10
1569P - Secondary delay in breast cancer diagnosis and role of rural medical practitioners: A cause and cure finding study
Presenter: Rahul Agarwal
Session: Poster session 10
1570P - Factors and impacts of delayed presentation for county-level patients with breast cancer in a real-life setting in China
Presenter: Yinghua Ji
Session: Poster session 10
1571P - The reasons that motivate a change of specialties among oncology residents
Presenter: Christophe Ducrocq
Session: Poster session 10
1572P - Factors associated with career choice in oncology among medical students
Presenter: Nicolas Penel
Session: Poster session 10
1573P - Global cancer statistics for adolescents and young adults: New estimates from GLOBOCAN 2022
Presenter: Wang-Zhong Li
Session: Poster session 10
Resources:
Abstract